NY Times Challenges Trump Administration Subpoenas Over Air Force One Report 
Uber to Acquire Delivery Hero in $14.8 Billion Deal to Expand Global Food Delivery Business 
xAI Sues Man for Allegedly Using Grok to Generate AI Child Abuse Deepfakes 
Apple Intelligence Cleared for China as Alibaba and Baidu AI Power iPhone Features 
DeepSeek Eyes China IPO as AI Startup Seeks $71 Billion Valuation in New Funding Round 
Paramount-Warner Bros. Discovery Merger Faces Lawsuit From 12 States 
ASML Raises 2026 Outlook as AI Chip Demand Lifts Q2 Earnings 
Arm Stock Falls After HSBC Downgrade, Citing Limited Near-Term AI Upside 
DBS Targets S$1 Trillion Wealth AUM by 2030 Amid Asia Wealth Boom 
Hyundai Takes Full Control of Boston Dynamics to Accelerate Humanoid Robot and AI Strategy 
Jamie Dimon Warns Anthropic's Mythos AI Poses National Security Risks 
BHP Q4 Iron Ore Output Rebounds as Copper Prices Boost Revenue 
SpaceX Stock Falls Below IPO Price as Investors Weigh Losses and Lockup Expiry 
Taiwan Mangoes Head to Europe as Premium Fruit Exports Expand 
United Airlines Beats Q2 Earnings, Raises 2026 Profit Outlook Despite Higher Fuel Costs 
Rio Tinto Reports Strong Q2 Iron Ore Sales, Maintains 2026 Production Outlook 
Eli Lilly Eyes AtaiBeckley Acquisition to Expand Psychedelic Mental Health Pipeline 
SAN RAFAEL, Calif., Jan. 28, 2016 -- BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) today announced that Jean-Jacques Bienaimé, Chairman and Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 25, at 4:30 p.m. ET to discuss fourth quarter and full year 2015 financial results and provide a general business update.
Dial-in Number
U.S. / Canada Dial-in Number: (877) 303-6313
International Dial-in Number: (631) 813-4734
Conference ID: 34535772
Replay Dial-in Number: (855) 859-2056
Replay International Dial-in Number: (404) 537-3406
Conference ID: 34535772
Interested parties may access a live audio webcast of the conference call via the investor section of the BioMarin website, www.BMRN.com. A replay of the call will be archived on the site for one week following the call.
About BioMarin
BioMarin is a global biotechnology company that develops and commercializes innovative therapies for patients with serious and life-threatening rare and ultra-rare genetic diseases. The company's portfolio consists of five commercialized products and multiple clinical and pre-clinical product candidates. For additional information, please visit www.BMRN.com.
Contacts: Investors Traci McCarty BioMarin Pharmaceutical Inc. (415) 455-7558 Media Debra Charlesworth BioMarin Pharmaceutical Inc. (415) 455-7451
